[基于JAK2/STAT3通路的乙基酸对性结肠炎的保护作用]
Meng-di Liang1, Yue-Run Liang1, Jin Cheng1
1Ministry of Education Key Laboratory of Marine Drugs,School of Medicine and Pharmacy, Ocean University of China Qingdao 266005,China.
乙烯注射剂 (MD) 显示了治疗性结肠炎 (UC) 的治疗潜力. 它通过抑制JAK2/STAT3通路来减少炎症和修复肠道损伤,为UC提供了一种新的治疗策略.
科学领域:
- 药理学和治疗学 药理学和治疗学
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 了解UC背后的分子机制对于开发有效疗法至关重要.
研究的目的:
- 调查乙烯注射剂 (MD) 在性结肠炎 (UC) 中的治疗潜力和潜在机制.
- 评估MD对炎症反应,细胞增殖和JAK2/STAT3信号通路的影响.
主要方法:
- 细胞增殖的MTT测定,由LPS/TNF-α诱导的体外细胞模型,以及UC的DSS诱导的小鼠模型.
- 测量氧化 (NO),活性氧物种 (ROS),炎症性细胞因子 (IL-6,TNF-α,INF-γ,IL-10) 和髓氧化酶 (MPO).
- 西部斑点分析用于评估JAK2/STAT3通路激活和肠上皮质屏障蛋白 (ZO-1,ocludin,claudin-1).
主要成果:
- MD抑制了RAW264.7和HT-29细胞的增殖,并减少了NO和ROS的产生.
- 在UC小鼠模型中,MD治疗显著降低了疾病活性指数 (DAI),结肠缩短和炎症标志物.
- MD抑制了JAK2/STAT3通路的激活,并恢复了肠道上皮质屏障的完整性.
结论:
- 乙烯注射剂 (MD) 具有显著的抗性结肠炎活性.
- 通过减轻炎症,减少氧化应激,并抑制JAK2/STAT3信号通路,MD改善UC.
- MD显示为治疗性结肠炎的治疗药物有前途.
更多相关视频
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
08:15Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease
Published on: May 10, 2024
相关概念视频
The JAK-STAT Signaling Pathway
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
